<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00794144</url>
  </required_header>
  <id_info>
    <org_study_id>C-07-02</org_study_id>
    <nct_id>NCT00794144</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to &lt; 6 Years of Age</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety of the study drug, Patanase (Olopatadine
      Hydrochloride Nasal Spray 0.6%) compared to placebo (inactive substance) in children ages 2
      to less than 6 who have a history of nasal allergies, and to assess the pharmcokinetics
      (study of the action of a drug in the body) in these children
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Anatomic Nasal Exam Abnormalities</measure>
    <time_frame>Day 1 (Baseline) to Exit</time_frame>
    <description>The appearance in a participant of any of the following from Baseline: anatomic abnormalities, evidence of infection, bleeding, and/or ulcerations of the mucosa</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olopatadine Hydrochloride Nasal Spray 0.6%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olopatadine Hydrochloride Nasal Spray Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine Hydrochloride Nasal Spray 0.6%</intervention_name>
    <description>one spray in each nostril twice daily for 2 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine Hydrochloride Nasal Spray Vehicle</intervention_name>
    <description>one spray in each nostril twice daily for 2 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be at least 2 years of age and less than 6 years of age on Day 1;

          -  Parent/legal guardian must be willing and able to give written informed consent and
             must provide this consent for the study;

          -  Patient must have a positive case history of allergic rhinitis symptoms and at least
             one documented positive skin test within the 5 years prior to Day 1 of the following
             type: skin prick test, intradermal test or RAST test(radioallergosorbent test) for an
             allergen (≥ 3 mm wheal greater than diluent after skin prick testing; ≥ 7 mm wheal
             greater than the diluent after intradermal testing; or positive level 2 or greater
             after RAST testing);

          -  Patient and parent/caregiver must be willing and able to make required study visits;

          -  Patient and parent/caregiver must be able to follow instructions;

          -  Nasal exam must confirm absence of significant anatomic abnormalities, infection,
             bleeding, and mucosal ulcerations at Screening and prior to administration of test
             article at the Day 1 Visit. A finding of 'present' for any of these parameters
             disqualifies the patient from the study, regardless of clinical relevance.

        Exclusion Criteria:

          -  The need for chronic or intermittent use of any prescription or over-the-counter nasal
             spray during the study period;

          -  Use of any form of olopatadine (e.g., PATANOL®, PATADAY™, PATANASE®) within 7 days of
             Day 1;

          -  Current or recent (within the last 14 days) use of any drugs/drug classes or
             combinations thereof that may prolong the QT interval;

          -  Patients with a history or evidence of nasolacrimal drainage system malfunction or
             abnormality that may interfere with the results of the study;

          -  Concurrent disease that might complicate or interfere with the investigation or
             evaluation of the study medications (such as rhinitis medicamentosa or large
             obstructive nasal polyps);

          -  Patients with syndromes associated with midfacial deformities or other anatomic nasal
             deformity that may interfere with the patient's participation in the study, as
             identified by physical or nasal examination at Screening or Day 1;

          -  Diagnosis of acute sinusitis within 30 days of Day 1 or diagnosis of chronic
             rhinosinusitis within one year of Day 1;

          -  Congestion that would, in the opinion of the investigator, interfere with successful
             nasal drug administration/absorption (in either nostril);

          -  Upper or lower respiratory infection within 14 days of Day 1;

          -  Asthma, with the exception of intermittent asthma as outlined in Section 18.5, from
             the Stepwise Approach for Managing Asthma in Children 0-4 Years of Age, and Stepwise
             Approach for Managing Asthma in Children 5-11 Years of Age (5);

          -  Current or recent (&lt; 6 months) history of severe, unstable, or uncontrolled
             neurological, cardiovascular, gastrointestinal, hematological, hepatic, and/or renal
             disease, or evidence of other diseases at the physical examination conducted at the
             Screening Visit, which in the opinion of the Investigator would preclude the safe
             participation of the patient in the study;

          -  Hypersensitivity to olopatadine, benzalkonium chloride, or any component of the test
             articles;

          -  History or current infection of HIV (Human Immunodeficiency Virus), hepatitis B or C
             or A, as indicated by the patient's parent or legal guardian response on the
             HIV/Hepatitis survey;

          -  Relatives of study site staff or other individuals who would have access to the
             clinical study protocol;

          -  A family member or any individual residing in the same household of a patient that is
             currently enrolled in the study;

          -  Participation in any other investigational study within 30 days before entry into this
             study (Day 1), or concomitantly with this study;

          -  Clinically relevant abnormal vital signs (pulse rate, average systolic and diastolic
             blood pressure) at Screening or Day 1. The ranges below have been designated as normal
             for the study. Inclusion of patients with values outside of these normal ranges is at
             the discretion of the study investigator;

        Normal Cardiovascular Ranges

          -  Systolic Blood Pressure — 86 to 116 mmHg (millimeters mercury)

          -  Diastolic Blood Pressure —50 to 78 mmHg

          -  Pulse — 75 to 130 bpm (beats per minute)

        In addition, the Alcon Medical Monitor and/or Principal Investigator may declare any
        patient ineligible for the study based upon sound medical reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niran Amar, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Sheri Byrd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spartanburg Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albert Finn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Allergy, Asthma, &amp; Urticaria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Flanagan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Sciences Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brad H Goodman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aeroallergy Research Laboratories</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Hampel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Texas Allergy and Asthma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yu-Luen Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Coast Clinical Trials Phase 2-4</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neil Kao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allergic Disease and Asthma Cente</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Prestigiacomo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gulf Coast Research Associates, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Ratner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sylvana Research Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asthma and Allergy Associates, P.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Niran Amar, M.D.</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2008</study_first_submitted>
  <study_first_submitted_qc>November 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2008</study_first_posted>
  <results_first_submitted>January 12, 2010</results_first_submitted>
  <results_first_submitted_qc>January 12, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2010</results_first_posted>
  <last_update_submitted>February 23, 2010</last_update_submitted>
  <last_update_submitted_qc>February 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Cynthia M. Rusk\Manager, Development</name_title>
    <organization>Alcon Research</organization>
  </responsible_party>
  <keyword>Allergic Rhinitis</keyword>
  <keyword>Pediatric</keyword>
  <keyword>PATANASE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients at medical clinics in the U.S. participated from October 03, 2008, through December 03, 2008.</recruitment_details>
      <pre_assignment_details>negative allergic response; enrollment target met</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olopatadine Hydrochloride Nasal Spray 0.6%</title>
          <description>Olopatadine Hydrochloride Nasal Spray 0.6%</description>
        </group>
        <group group_id="P2">
          <title>Olopatadine Hydrochloride Nasal Spray Vehicle</title>
          <description>Olopatadine Hydrochloride Nasal Spray Vehicle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olopatadine Hydrochloride Nasal Spray 0.6%</title>
          <description>Olopatadine Hydrochloride Nasal Spray 0.6%</description>
        </group>
        <group group_id="B2">
          <title>Olopatadine Hydrochloride Nasal Spray Vehicle</title>
          <description>Olopatadine Hydrochloride Nasal Spray Vehicle</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="132"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Anatomic Nasal Exam Abnormalities</title>
        <description>The appearance in a participant of any of the following from Baseline: anatomic abnormalities, evidence of infection, bleeding, and/or ulcerations of the mucosa</description>
        <time_frame>Day 1 (Baseline) to Exit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olopatadine Hydrochloride Nasal Spray 0.6%</title>
            <description>Olopatadine Hydrochloride Nasal Spray 0.6%</description>
          </group>
          <group group_id="O2">
            <title>Olopatadine Hydrochloride Nasal Spray Vehicle</title>
            <description>Olopatadine Hydrochloride Nasal Spray Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anatomic Nasal Exam Abnormalities</title>
          <description>The appearance in a participant of any of the following from Baseline: anatomic abnormalities, evidence of infection, bleeding, and/or ulcerations of the mucosa</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 Weeks (Day 1 to Exit)</time_frame>
      <desc>Adverse events volunteered and solicited</desc>
      <group_list>
        <group group_id="E1">
          <title>Olopatadine Hydrochloride Nasal Spray 0.6%</title>
          <description>Olopatadine Hydrochloride Nasal Spray 0.6%</description>
        </group>
        <group group_id="E2">
          <title>Olopatadine Hydrochloride Nasal Spray Vehicle</title>
          <description>Olopatadine Hydrochloride Nasal Spray Vehicle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (version 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alcon Clinical</name_or_title>
      <organization>Alcon Research Ltd</organization>
      <phone>888.451.3937; 817.568.6725</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

